Sage Therapeutics, Inc. (SAGE) Hits New 1-Year High on Analyst Upgrade

Leslie Hanson
November 12, 2017

The investment objective of the Fund is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with protection of invested capital.

Insider Trading Activity for Sage Therapeutics, Inc. Sage Therapeutics, Inc. has a 12 month low of $44.55 and a 12 month high of $98.80. Finally, Amalgamated Bank purchased a new stake in shares of Sage Therapeutics during the first quarter valued at $262,000. Bankshares Of America Corporation De stated it has 0% in SAGE Therapeutics Inc (NASDAQ:SAGE). It is down 5.22% since November 10, 2016 and is downtrending. About 1.75 million shares traded or 182.39% up from the average. It has outperformed by 99.75% the S&P500.

So what to make of SAGE Therapeutics Inc's (NASDAQ:SAGE) latest success? Therefore 81% are positive.

SAGE has been the subject of a number of other reports. One analyst has rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. On Tuesday, September 12 the stock rating was maintained by Leerink Swann with "Buy". The rating was maintained by H.C. Wainwright on Friday, August 4 with "Hold".

Sage's shares soared as much as 54.8 percent to an all-time high of $96.99, before paring some gains. Cowen & Co initiated Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) on Tuesday, September 8 with "Outperform" rating. The company now has a consensus rating of "Buy" and an average target price of $70.23. Of those insider trades, 0 shares of Sage Therapeutics, Inc. were purchased and 545,000 shares were sold. The firm has "Buy" rating given on Thursday, November 2 by RBC Capital Markets. The return on invested capital is at 0%, which is good, compared to its peers. 1 analysts say it's a Hold while 0 analysts provided their expert opinion as Sell. Of those transactions, there were 2,174 shares of SAGE bought and 2.37 million shares sold. Victory Cap Mngmt owns 445,485 shares. Parametric Port Assocs Ltd has 22,535 shares. Teacher Retirement System of Texas purchased a new stake in shares of Sage Therapeutics during the second quarter valued at $202,000. Highland Capital Management Limited Partnership holds 0.08% or 24,300 shares in its portfolio. Cutter And Brokerage holds 5,296 shares or 0.17% of its portfolio. More interesting news about SAGE Therapeutics Inc (NASDAQ:SAGE) were released by: and their article: "SAGE Therapeutics: Postpartum Depression Play" published on November 06, 2017 as well as's news article titled: "Sage Therapeutics Appoints Asha Nayak, MD, Ph.D., to Board of Directors" with publication date: November 08, 2017. Oak Ridge Investments Ltd holds 729,874 shares. Franklin Resources invested 0.02% in SAGE Therapeutics Inc (NASDAQ:SAGE). Oppenheimer Asset Mngmt Incorporated invested in 0% or 379 shares.

Sage Therapeutics (NASDAQ:SAGE) opened at 47.95 on Thursday.

The company now has an insider ownership of 0.9 Percent and Institutional ownership of 0 Percent. Global X Management Ltd Liability holds 0% or 210 shares in its portfolio. Pecaut & Co. owns 81,238 shares or 2.6% of their USA portfolio. The New Jersey-based Bulldog Investors Llc has invested 1% in the stock.

Investors sentiment decreased to 0.98 in 2017 Q2.

Other reports by Iphone Fresh

Discuss This Article